Mirum Pharmaceuticals, Inc. MIRM

89.70 0.34 0.38% as of 25 Sep
Market cap
$5.8B
P/E
0.0×
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(702.97%) (335.82%) (8.65%) (15.81%)

+8 more TTM periods

ROA
(97.15%) (101.04%) (3.09%) (5.70%)
ROIC
(172.96%) (298.98%) (5.74%) (11.56%)
Return on Tangible Assets
(206.89%) (267.15%) (6.76%) (11.15%)
Average Days of Receivables
85.84 85.30 86.35 82.88
Free Cash Flow per Share
(4.32) (3.44) 1.09 0.88
Free Cash Flow
(273.74) (202.55) 54.87 44.32
Capital Expenditures
(46.47) (31.58) (0.95) (0.37)
Piotroski F-Score
3.00 4.00 6.00 6.00
Other line items
Cash ROIC
(19.29%) (18.21%) 5.54% 4.57%
Accounts Receivable Turnover
4.90 4.98 5.17 5.37
Accounts Payable Turnover
5.50 2.99 8.27 8.73
Inventory Turnover
4.64 4.42 4.24 4.15
Average Days of Payables
75.70 204.48 35.01 46.87
Days of Inventory on Hand
83.27 87.85 90.62 92.53
Tax Rate
0.00 0.00 0.09 0.01
Research and Development Expense of Revenue
165.88% 169.30% 35.71% 37.96%
Selling, General and Administrative Expense of Revenue
50.78% 51.90% 49.30% 50.81%
Share Based Compensation of Revenue
16.82% 16.12% 13.70% 13.91%
Interest Coverage
0.00 0.00 0.00 0.00
Operating CF/Net income
0.26 0.21 (2.39) (1.08)
Depreciation/Fixed assets
12.41 11.12 13.95 20.32
Capex/Depreciation
(1.66) (1.18) (0.04) (0.01)
Revenue per Share
9.75 9.68 10.39 9.32
Operating CF per Share
(3.59) (2.91) 1.11 0.88
Capex per Share
(0.73) (0.54) (0.02) (0.01)
Capex to Sales
0.08 0.06 0.00 0.00
Net Profit Margin
(139.18%) (140.24%) (4.48%) (8.78%)

Fold the line items

Columns are period end dates